News for 'GSK Consumer Healthcare'

GSK Consumer Healthcare makes open offer for 31.8%

GSK Consumer Healthcare makes open offer for 31.8%

Rediff.com26 Nov 2012

Post the offer, GSK's holding will be 75 per cent from the present 43.2 per cent.

Stay invested, more gains in the offing for GSK Consumer

Stay invested, more gains in the offing for GSK Consumer

Rediff.com27 Nov 2012

Given the strong prospects in the business, analysts expect the company to clock healthy growth of 15-20 per cent, going ahead.

GSK overtakes Colgate in sensitivity segment: Nielsen

GSK overtakes Colgate in sensitivity segment: Nielsen

Rediff.com18 Apr 2013

The sensitivity segment has quadrupled in the past two years, due to the aggressive marketing effort of both GSK and Colgate.

Regulatory pain for GSK's Crocin Advance

Regulatory pain for GSK's Crocin Advance

Rediff.com28 Mar 2014

The NPPA letter was issued to GSK on Wednesday.

'GSK-Novartis deal not to impact India business'

'GSK-Novartis deal not to impact India business'

Rediff.com22 Apr 2014

The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.

Post HUL deal, 4,000 GSK employees' fate in limbo

Post HUL deal, 4,000 GSK employees' fate in limbo

Rediff.com11 Dec 2018

While a merger means HUL taking over GSK Consumer's assets, including its employees, any mention of retention of employees beyond the merger is missing in the deal.

GSK to spend $904 mn to lift stake in India arm

GSK to spend $904 mn to lift stake in India arm

Rediff.com27 Nov 2012

Open offer to increase holding to 75%, fails to enthuse institutional investors.

Crocin Quick gives GSK a headache

Crocin Quick gives GSK a headache

Rediff.com27 Sep 2005

Novartis buys GSK's cancer drugs for $16 bn in three-part deal

Novartis buys GSK's cancer drugs for $16 bn in three-part deal

Rediff.com22 Apr 2014

In separate statements, the two companies said they will combine Novartis' over-the-counter division with GSK's consumer business, creating a new world-leading consumer healthcare business with $10 billion in annual sales.

GSK raises stake in Indian arm to 72.5%

GSK raises stake in Indian arm to 72.5%

Rediff.com5 Feb 2013

The company is increasing its exposure to key emerging markets.

GSK slashes price of Crocin tablets

GSK slashes price of Crocin tablets

Rediff.com22 Apr 2014

GSKAP takes care of all non-nutrition products whereas GSK Consumer Healthcare is a listed entity which deals only in nutritional products.

How Amway grew bigger than Procter & Gamble, Gillette in India

How Amway grew bigger than Procter & Gamble, Gillette in India

Rediff.com29 May 2013

Amway surged by converting a multitude into sales agents.

Novartis-GSK-Eli Lilly deal may affect Indian market

Novartis-GSK-Eli Lilly deal may affect Indian market

Rediff.com23 Apr 2014

On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.

GSK will pay $3 bn to settle US drug row

GSK will pay $3 bn to settle US drug row

Rediff.com4 Nov 2011

The 'in-principle' settlement of $3 billion is covered by existing provisions. GSK expects to make payments under a final agreement next year.

Taapsee, Madhavan and the remaking of an old favourite

Taapsee, Madhavan and the remaking of an old favourite

Rediff.com21 Mar 2018

Horlicks widens brand appeal in increasingly competitive market.

Everyone wants health in a bottle!

Everyone wants health in a bottle!

Rediff.com29 Aug 2017

As competition heats up, health drink brands like GSK, Mondelez, Nestle get more aggressive with promotions and promises.

HUL gets Rs 963 cr Income Tax demand notice

HUL gets Rs 963 cr Income Tax demand notice

Rediff.com28 Aug 2024

Leading FMCG maker HUL said that it has received a demand notice of Rs 962.75 crore from the Income Tax Department and will go in for an appeal against the order. The notice relates to non-deduction of TDS on payment of Rs 3,045 crore to GlaxoSmithKline Consumer Healthcare (GSKCH) for the acquisition of Intellectual Property Rights of the Health Foods Drinks (HFD) business consisting of brands as Horlicks, Boost, Maltova, and Viva, according to a recent exchange filing.

HUL finally acquires Horlicks for Rs 3,045 cr

HUL finally acquires Horlicks for Rs 3,045 cr

Rediff.com1 Apr 2020

Other Health Food Drinks brands of GSK -- Boost, Maltova and Viva -- would come to HUL's portfolio by virtue of the merger, making it a leading player in the segment.

Consumer goods makers see little gain from the new govt

Consumer goods makers see little gain from the new govt

Rediff.com19 May 2014

Growth in cities has lagged villages as consumers troubled by persistently high inflation have cut spending in the past two years.

Licious gears up for IPO with new CFO, profit pursuit

Licious gears up for IPO with new CFO, profit pursuit

Rediff.com29 May 2024

Fresh meat and seafood delivery unicorn Licious is intensifying its talent acquisition endeavours as it pursues profitability and readies for an initial public offering (IPO) within the next 24 months. Delightful Gourmet, Licious' parent company, has named 39-year-old Karishma Gupta as its new chief financial officer (CFO). Her appointment aligns with Licious' drive for profitable growth through an omnichannel strategy.

HUL-GlaxoSmithKline merger leads to Rs 31,700 cr entity

HUL-GlaxoSmithKline merger leads to Rs 31,700 cr entity

Rediff.com3 Dec 2018

The transaction is an all equity merger with 4.39 shares of HUL being allotted for every share in GlaxoSmithKline Consumer Healthcare India

FIIs trim stake in FMCG companies during Jan-Mar quarter

FIIs trim stake in FMCG companies during Jan-Mar quarter

Rediff.com2 May 2014

FIIs have offloaded shares of Bajaj Corp, Nestle, Jyothy Laboratories and Britannia.

HUL's growth checkout: Navigating the low-volume aisle in Q3 FY24

HUL's growth checkout: Navigating the low-volume aisle in Q3 FY24

Rediff.com18 Dec 2023

There is no near-term respite for the country's largest fast-moving consumer goods maker, Hindustan Unilever (HUL), which is facing multiple challenges on the growth front. With demand showing no signs of improvement, especially in the rural segment, the October-December quarter (Q3) of 2023-24 (FY24) is likely to be similar to the previous quarter, with volume growth in the low single digits. The stock, which is down 7 per cent over the past year compared to the 11 per cent jump for the S&P BSE Sensex, could underperform the benchmark in the near term as well.

HUL appoints Rohit Jawa as new MD & CEO

HUL appoints Rohit Jawa as new MD & CEO

Rediff.com11 Mar 2023

FMCG major HUL on Friday announced the appointment of Rohit Jawa as the managing director & chief executive officer to succeed Sanjiv Mehta who will retire from the company after leading it for a decade. Jawa, presently the Chief of Transformation for Unilever, would take over the leadership role for a term of five consecutive years with effect from June 27, 2023, the company said in a statement. "The appointment of Rohit Jawa as a whole-time director and MD & CEO will be subject to approval of Shareholders and other statutory approvals as may be applicable," it added.

ITC pushes Yippee noodles to replace Maggi

ITC pushes Yippee noodles to replace Maggi

Rediff.com13 Jun 2015

ITC has provided retailers with leaflets to assure customers of Yippee noodle's quality and safety standards

How drug firms dodge government rules

How drug firms dodge government rules

Rediff.com5 Aug 2013

A probe finds several pharma majors in breach of the law; and in turn they blame the government.

ITC goes in for more tests of its products

ITC goes in for more tests of its products

Rediff.com8 Jun 2015

ITC on Monday said it is conducting more tests on its products at accredited labs across India.

FIs turn down Glaxo's open-offer price

FIs turn down Glaxo's open-offer price

Rediff.com8 Jan 2013

The British pharma and consumer products maker had announced the open offer in November last year to raise its stake in its subsidiary to 75 per cent from 43.16 per cent at present.

HUL switches to green fuel; becomes coal free across biz

HUL switches to green fuel; becomes coal free across biz

Rediff.com2 Dec 2021

Leading FMCG firm HUL on Thursday said it has switched to green fuel alternatives such as biomass and biodiesel and has eliminated the usage of coal across its operations. The company has collaborated with biomass suppliers and local farmers to ensure sustainable supply of green fuel and has made the necessary changes for the renewable transition in its coal-fired boilers, said an HUL statement. Besides, the shift from coal to renewable energy sources has also resulted in savings for the company, it added.

Glaxo interested in Indian acquisitions

Glaxo interested in Indian acquisitions

Rediff.com9 Mar 2010

GlaxoSmithKline, the world's second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value.

Unilever open offer for HUL subscribed 66%

Unilever open offer for HUL subscribed 66%

Rediff.com5 Jul 2013

Anglo-Dutch parent's stake in Indian subsidiary rises from 52.5% to 67.3%.

How HUL and P&G are shaping their India strategy

How HUL and P&G are shaping their India strategy

Rediff.com23 Dec 2019

While Unilever has been aggressive, both organically and inorganically in the country, P&G's approach has been about achieving 'balanced growth' in terms of top line and bottom line.

Firms should invest in right talent to sustain growth

Firms should invest in right talent to sustain growth

Rediff.com11 Aug 2014

This goes a long way in creating an ethical organisation culture that in turn helps attract talent.

India Inc's growing disconnect between profits and dividends

India Inc's growing disconnect between profits and dividends

Rediff.com12 Dec 2014

Some big ones hoard cash unduly and others borrow to keep up payments to shareholders

40 years....and now: How Horlicks grew up with the times

40 years....and now: How Horlicks grew up with the times

Rediff.com2 Oct 2014

Advertising taglines such as 'Bright in studies, bright in sports' attempted to drive home the message that Bournvita, a chocolate drink, could build a child's mental and physical faculties.

2018: Year of reckoning for India Inc

2018: Year of reckoning for India Inc

Rediff.com28 Dec 2018

A glance back at some of the important ups and down Indian Inc faced in 2018.

Global FMCG majors bet big on India despite slowdown

Global FMCG majors bet big on India despite slowdown

Rediff.com25 Dec 2013

India was the flavour of the year, at least in the FMCG sector, as multinationals hiked stakes in their subsidiaries lured by long term potential of the country, while homegrown executives made their way to top hierarchy of global firms in 2013.

2015 may be a year of deal making for FMCG sector

2015 may be a year of deal making for FMCG sector

Rediff.com11 Jan 2015

@015 may be a good year for FMCG firms.

Looking at MNC stocks? Think again

Looking at MNC stocks? Think again

Rediff.com24 Jun 2013

If you are not happy with the price offered at buybacks, you could be in for a long haul.